MPO and neoplasm: We initially used a model designed for highest efficacy in tumor rejection (Fig. 4a–c), revealing comparably potent rejection kinetics for neoTCRs—previously known and now additionally identified—compared to the irrelevant, MPO-specific TCR-control (2.5D6)31.